Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-018694

CHIEF FINANCIAL OFFICER sold 4,250 shares at an average $22.57 ($95,922)

  • CHIEF FINANCIAL OFFICER acquired 4,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-06-27 Option exercise 10b5-1 +4,250 $2.48 $10,540 4,250 D: show line 1 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-06-27 Sale 10b5-1 −1,280 $21.79 $27,897 2,970 D: show line 2 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-06-27 Sale 10b5-1 −1,830 $22.58 $41,313 1,140 D: show line 3 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-06-27 Sale 10b5-1 −1,140 $23.43 $26,711 0 D: show line 4 in the form
Open-market sales · 4,250 sh · avg $22.57 · $95,922

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-06-27 Option exercise · Stock Option (right to buy) 10b5-1 −4,250 212,620 D: show line 5 in the form
Loading xslF345X05/form4-07022024_120743.xml…